Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders
- 1 August 1992
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 40 (4) , 283-289
- https://doi.org/10.1002/ajh.2830400408
Abstract
Thrombotic and hemorrhagic disorders are common complications of the myeloproliferative disorders. Endothelial cells release both procoagulant and profibrinolytic factors, which may contribute to these hemorrhagic or thrombotic complications. The pre- and postvenous stasis levels of the procoagulant and profibrinolytic factors produced by endothelial cells were correlated with the occurrence of complications in polycythemia rubra vera (PRV) patients (n = 29) and essential thrombocythemia (ET) patients (n = 17) compared with normal patients (n = 17). Tissue plasminogen activator (tPA) activity, plasminogen activator inhibitor (PAI) activity, von Willebrand's factor (vWF) activity and antigen (vWF:Ag), and factor VIII activity were measured. The resting tPA activity was significantly higher in the two disease groups compared with normal controls, but no difference between the levels of tPA and either complication within the disease groups was observed. Significantly elevated tPA following venous stasis was observed in the patients of both disease groups who had bleeding complications. Significant decreases, compared with the normal group, in both resting and postvenous stasis levels of PAI were observed in the disease groups regardless of complication history. The subjects from both disease groups with thrombotic complications had significantly elevated resting vWF and both resting and postvenous stasis vWF:Ag levels compared with normal controls. The endothelial cell is likely to be responding to abnormal hemastasis rather than being primarily involved in the genesis of a hyper- or hypocoaguable state.Keywords
This publication has 54 references indexed in Scilit:
- Tissue plasminogen activator levels in different types of polycythemiaEuropean Journal of Haematology, 2009
- Essential Thrombocythemia in Young AdultsMayo Clinic Proceedings, 1991
- The management of thrombocytosisEuropean Journal of Haematology, 1990
- Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implicationsThe American Journal of Cardiology, 1989
- Essential thrombocythemia. Clinical characteristics and course of 61 casesCancer, 1988
- Anagrelide: A New Drug for Treating ThrombocytosisNew England Journal of Medicine, 1988
- Acute leukemia and myelodysplasia in polycythemia vera.A clinical study with long-term follow-upCancer, 1988
- Essential thrombocythemias. Clinical evolutionary and biological dataCancer, 1986
- VASCULAR OCCLUSIVE EPISODES AND VENOUS HÆMATOCRIT IN PRIMARY PROLIFERATIVE POLYCYTHÆMLXPublished by Elsevier ,1978
- LOW FIBRINOLYTIC ACTIVITY IN THE WALLS OF VEINS IN PATIENTS WITH THROMBOSISActa Medica Scandinavica, 1969